Business Context and Reporting Period
This Form 8-K is filed by Heatwurx, Inc. (not Processa Pharmaceuticals, Inc.) for the reporting period ending June 30, 2015. The company is a Delaware corporation based in Gardena, CA, focused on asphalt paving assets and intellectual property.
Key Financial Metrics
The filing details a specific debt restructuring event rather than comprehensive financial statements.
- Debt Converted: $174,360.52 of secured debt maturing on June 30, 2015.
- Debt Offering: The converted amount was rolled into a current $2,000,000 debt offering with the same lenders, which commenced on February 16, 2015.
- Revenue, Profit, Cash Flow, Margins: The filing text does not provide a clear value for these metrics.
- Liquidity: The filing text does not provide a clear value for general liquidity positions beyond the specific debt conversion.
Material Changes
On June 30, 2015, the Company entered into a Debt Conversion Agreement with JMW Fund, LLC, Richland Fund, LLC, and San Gabriel Fund, LLC. This action resulted in:
- Conversion of $174,360.52 in maturing secured debt into the existing $2,000,000 debt offering.
- Termination of the Loan Agreement dated December 11, 2013, between Dr. Pave LLC (a wholly-owned subsidiary) and the Lenders.
- Cancellation of senior secured notes in the principal amount of $160,000 and the associated Security Agreement dated December 11, 2013.
Outlook, Risks, and Management Commentary
On July 7, 2015, the Company issued a press release indicating that its asphalt paving assets and intellectual property are available for sale or merger. This suggests a potential strategic shift or liquidity event. The filing notes that the press release information is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the terms and interest rates of the new $2,000,000 debt offering into which the old debt was converted.
- Confirm the status of the proposed sale or merger of asphalt paving assets and IP mentioned in the July 7, 2015 press release.
- Review the full Debt Conversion Agreement (Exhibit 99.1) for covenants or collateral requirements.
- Clarify the discrepancy between the company name in the metadata (Processa Pharmaceuticals) and the registrant in the filing (Heatwurx, Inc.).